Annual Report 2019

MANAGEMENT DISCUSSION AND ANALYSIS 11 The United Laboratories International Holdings Limited Annual Report 2019 Intermediate Products and Bulk Medicine The Group’s intermediate products and bulk medicine recorded segment external sales of RMB1,280.4 million and RMB3,593.1 million respectively, representing year-on-year growth of 3.8% and 6.0% respectively. During the year, the price of semi-synthetic penicillin bulk medicine fluctuated slightly, and the price of 6-APA gradually decreased to a low level as the market supply capacity recovered, thus resulting impact on revenue and result of intermediate products segment. In respect of export, in the face of the challenges in the international pharmaceutical bulk medicine market and the slower growth of China’s imports and exports, the Group continued to optimise its product mix, deepen its development of global key pharmaceutical markets, and adhere to the international development, resulting in steady growth in export sales. During the year, the Group’s overseas export recorded a sales revenue of RMB2,435.0 million, representing an increase of 23.7% over last year. Executive directors from left to right: Ms. Choy Siu Chit, Mr. Leung Wing Hon, Ms. Zou Xian Hong, Mr. Tsoi Hoi Shan, Ms. Zhu Su Yan and Mr. Fang Yu Ping